Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhancer: LB-100 plus Doxorubicin in Advanced Soft Tissue Sarcomas
NCT05809830Phase 2Active, not recruiting
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LB-100 in soft tissue sarcoma (STS), sponsored by Spanish Group for Research on Sarcoma. Started May 2023; status: active, not recruiting.
02
Drugs
LB-100
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05809830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809830.